Difference between revisions of "Degarelix (Firmagon)"
m |
m |
||
| Line 17: | Line 17: | ||
==Also known as== | ==Also known as== | ||
| − | + | *'''Code name:''' FE200486 | |
| + | *'''Generic name:''' degarelix acetate | ||
| + | *'''Brand name:''' Firmagon | ||
==References== | ==References== | ||
| Line 23: | Line 25: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Subcutaneous medications]] | ||
[[Category:Endocrine therapy]] | [[Category:Endocrine therapy]] | ||
[[Category:GnRH antagonists]] | [[Category:GnRH antagonists]] | ||
Revision as of 02:06, 28 November 2017
General information
Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels. There is no initial testosterone surge/flare with degarelix, in contrast to GnRH agonists.[1][2][3]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 12/24/2008: FDA approved "for treatment of patients with advanced prostate cancer."
Also known as
- Code name: FE200486
- Generic name: degarelix acetate
- Brand name: Firmagon